RxDoctor Payments Data

Hassan Ahmad, MD

Allergy & Immunology · Chesterfield, MONPI 1194138024

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (41.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi accounts for 60.2% of it on its own, with 41 other manufacturers making up the rest. Reporting peaked in 2023 at $8,853 and has fallen 80.9% since, to $1,688 in 2025.

$15,219in general payments, 2019–2025

Across 272 payments — averaging $55.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$9K
  • Intuitive Surgical$1K
  • CSL Behring$870
  • Regeneron Healthcare Solutions, Inc.$819
  • GSK$377
  • Optinose US, Inc.$362
  • plus $3K from 36 others

What the payments were for

  • Consulting fees$6,38142%
  • Grants$7005%
  • Travel & lodging$2,15214%
  • Food & beverage$5,82638%
  • Education$1591%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,219 in reported general payments places this provider in the 80th percentile of 61 allergy & immunology providers in Missouri.

See all allergy & immunology providers in Missouri

Medicare billing

Part B allowed, 2024
$63,566
Medicare patients
173
Services billed
2,937

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5057$317,258
XolairOmalizumab15$41,116
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$14,875
XhanceFluticasone Propionate23$14,065
Breo ElliptaFluticasone/Vilanterol23$9,140
Epinephrine47$6,302
Arnuity ElliptaFluticasone Furoate13$4,290
Ipratropium Bromide131$2,221
Azelastine Hcl94$1,650
Fluticasone Propionate48$735
Famotidine39$623
Albuterol Sulfate HfaAlbuterol Sulfate21$375
Triamcinolone Acetonide36$279
Montelukast Sodium19$267
Methylprednisolone19$96

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra$870$317,25857 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$377$28,30455 claims
Optinose US, Inc.Xhance$362$14,06523 claims
Hikma Pharmaceuticals USAEpinephrine$19$6,30247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 61 allergy & immunology providers in Missouri.

Other allergy & immunology in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →